vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2021-3-192-197vtio-1344Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSМеханизмы развития и факторы риска возникновения злокачественных новообразований у реципиентов солидных органовPost-transplant malignancies in solid organ recipients: development mechanisms and risk factorsНикулинА. В.NikulinA. V.

Никулин Андрей Владимирович

123182, Москва, ул. Щукинская, д. 1

Andrey V. Nikulin

1, Shchukinskaya str., Moscow, 123182

nikulin5642@gmail.comПашковИ. В.PashkovI. V.

Москва

Moscow

ЯкунинЯ. С.YakuninY. S.

Москва

Moscow

ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияShumakov National Medical Research Center of Transplantology and Artificial OrgansRussian Federation202117092021233192197Copyright © Никулин А.В., Пашков И.В., Якунин Я.С., 20212021Никулин А.В., Пашков И.В., Якунин Я.С.Nikulin A.V., Pashkov I.V., Yakunin Y.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1344

По данным международного агентства по изучению рака, за 2020 год в мире выявлено 19 292 789 новых случаев заболеваемости раком различных локализаций и 9 958 133 пациента умерло от рака. Эти пугающие цифры наглядно показывают актуальность проблемы развития злокачественных новообразований у населения. Риск развития злокачественных новообразований у реципиентов солидных органов в 2–6 раз выше, чем в популяции. С учетом неуклонно возрастающего количества трансплантаций солидных органов во всем мире и постепенного увеличения продолжительности жизни реципиентов донорских органов изучение вопросов, касающихся факторов риска и механизмов развития, является актуальной задачей.

According to the International Agency for Research on Cancer, there were an estimated 19,292,789 new cancer cases in various localizations and 9,958,133 cancer deaths worldwide in 2020. These frightening figures clearly show that malignancies among the population is a pressing matter. The risk of post-transplant malignancy in solid organ recipients is 2–6-times higher than in the general population. Given the steadily increasing number of solid organ transplants worldwide and the gradual increase in life expectancy among organ recipients, studying the issues concerning risk factors and development mechanisms becomes a crucial task.

злокачественные новообразованиятрансплантациясолидные органыmalignant tumortransplantationsolid organReferencesRousseau-Gazaniol C et al. Lung cancer in renal transplant recipients: A case-control study. Lung Cancer. Elsevier Ireland Ltd. 2017; 111: 96–100. https://doi.org/10.1016/j.lungcan.2017.07.011.Katabathina V.S. et al. Malignancy after solid organ transplantation: Comprehensive imaging review. Radiographics. 2016; 36: 1390–1407. https://doi.org/10.1148/rg.2016150175Shtraichman O, Ahya VN. Malignancy after lung transplantation. Ann Transl Med. 2020; 8: 416–416. doi: 10.21037/atm.2020.02.126.González-Cruz C., Ferrándiz-Pulido C., García-Patos Briones V. Melanoma in Solid Organ Transplant Recipients. Actas Dermosifiliogr. 2020. https://doi.org/10.1016/j.adengl.2021.01.011Smedman TM et al. Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation – a retrospective study. Transpl Int. 2019; 11: 1144–1150. doi: 10.1111/tri.13471.Rousseau-Gazaniol C. et al. Lung cancer in renal transplant recipients: A case-control study. Lung Cancer. Elsevier Ireland Ltd. 2017; 111: 96–100. https://doi.org/10.1016/j.lungcan.2017.07.011D’Arcy ME et al. Survival after a cancer diagnosis among solid organ transplant recipients in the United States. Cancer. 2019; 6: 933–942. doi: 10.1002/cncr.31782.Acuna S.A. Etiology of increased cancer incidence after solid organ transplantation. Transplant. Rev. Elsevier Inc. 2018; 32: 218–224. https://doi.org/10.1016/j.trre.2018.07.001Guillemin A et al. Cancers solides après transplantation d’organe: épidémiologie, pronostic et spécificités de prise en charge. Bull Cancer. Société Française du Cancer. 2017; 104: 245–257. https://doi.org/10.1016/j.bulcan.2016.12.008.Vajdic C.M., Van Leeuwen M.T. Cancer incidence and risk factors after solid organ transplantation. Int. J. Cancer. 2009; 125: 1747–1754. https://doi.org/10.1002/ijc.24439Wareham NE et al. Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation. J Cancer Res Clin Oncol. Springer Berlin Heidelberg. 2019; 145: 3125–3135. https://doi.org/10.1007/s00432-019-03039-2.Asch W.S., Perazella M.A. Cancer and Mortality in Solid-Organ Transplantation: Preventable or Inevitable? Am. J. Kidney Dis. 2016; 68: 839–842. https://doi.org/10.1053/j.ajkd.2016.06.009Katabathina VS et al. Malignancy after solid organ transplantation: Comprehensive imaging review. Radiographics. 2016; 36: 1390–1407. https://doi.org/10.1148/rg.2016150175.Huo Z. et al. Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies. Oncoimmunology. Taylor & Francis. 2020; 9. https://doi.org/10.1080/2162402X.2020.1848068González-Cruz C, Ferrándiz-Pulido C, García-Patos Briones V. Melanoma in Solid Organ Transplant Recipients. Actas Dermosifiliogr. 2020. https://doi.org/10.1016/j.adengl.2021.01.011.Brennan D.C. et al. Development of malignancy following solid organ transplantation. UpToDate. 2016; 10: 1–20.Lizakowski S et al. Solid Organ Cancer and Melanoma in Kidney Transplant Recipients: TumorTx Base Preliminary Results. Transplant Proc. 2018; 6: 1881–1888. doi: 10.1016/j.transproceed.2018.02.146.Noone A.M. et al. Cancer-attributable mortality among solid organ transplant recipients in the United States: 1987 through 2014. Cancer. 2019; 125: 2647–2655.Benoni H et al. Survival among solid organ transplant recipients diagnosed with cancer compared to nontransplanted cancer patients – A nationwide study. Int J Cancer. 2020; 146: 682–691. doi: 10.1002/ijc.32299.Endén K. et al. Cancer morbidity and mortality after pediatric solid organ transplantation—a nationwide register study. Pediatr. Nephrol. Pediatric Nephrology. 2020; 35: 1719–1728. https://doi.org/10.1007/s00467-020-04546-yAcuna SA. Etiology of increased cancer incidence after solid organ transplantation. Transplant Rev. Elsevier Inc. 2018; 32: 218–224. https://doi.org/10.1016/j.trre.2018.07.001.Fogel A.L., Miyar M., Teng J.M.C. Cutaneous Malignancies in Pediatric Solid Organ Transplant Recipients. Pediatr. Dermatol. 2016; 33: 585–593.Hall EC et al. Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013; 119: 2300–2308. https://doi.org/10.1002/cncr.28043.Rademacher S. et al. The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients. Liver Transplant. 2017; 23: 1404–1414. https://doi.org/10.1002/lt.24795Lengwiler E et al. Solid cancer development in solid organ transplant recipients within the Swiss Transplant Cohort Study. Swiss Med Wkly. 2019; 149: 1–9. https://doi.org/10.4414/smw.2019.20078.Engels E.A. Cancer in Solid Organ Transplant Recipients: There Is Still Much to Learn and Do. Am. J. Transplant. 2017; 17: 1967–1969. https://doi.org/10.1111/ajt.14140Madeleine MM et al. Epidemiology of keratinocyte carcinomas after organ transplantation. Br J Dermatol. 2017; 177: 1208–1216. doi: 10.1111/bjd.15931.Legendre C. et al. Long-term challenges after solid organ transplantation: Summary of expert presentations from the Sandoz 5th standalone transplantation meeting, 2017. Transplantation. 2018; 102: 1–14. DOI: 10.1097/TP.0000000000002316Yanik EL et al. Comparison of cancer diagnoses between the US solid organ transplant registry and linked central cancer registries. Am J Transplant. 2016; 16: 2986–2993. https://doi.org/10.1111/ajt.13818.Wang X., Dong M. Malignancy After Lung Transplantation: How to Manage Immunosuppression? Transplant. Proc. Elsevier Inc. 2020; 52: 315–320. https://doi.org/10.1016/j.transproceed.2019.09.012Vajdic CM, Van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009; 125: 1747–1754. doi: 10.1002/ijc.24439.Yanik E.L. et al. Comparison of cancer diagnoses between the US solid organ transplant registry and linked central cancer registries. Am. J. Transplant. 2016; 16: 2986–2993. https://doi.org/10.1111/ajt.13818Asch WS, Perazella MA. Cancer and Mortality in SolidOrgan Transplantation: Preventable or Inevitable? Am J Kidney Dis. 2016; 68: 839–842. https://doi.org/10.1053/j.ajkd.2016.06.009.Liao J.B., Fisher C.E., Madeleine M.M. Gynecologic cancers and solid organ transplantation. Am. J. Transplant. 2019; 19: 1266–1277. https://doi.org/10.1111/ajt.15292Huo Z et al. Cancer Risks in Solid Organ Transplant Recipients: Results from a Comprehensive Analysis of 72 Cohort Studies. Oncoimmunology. Taylor & Francis. 2020; 9. doi: 10.1080/2162402X.2020.1848068.Hall E.C. et al. Cumulative incidence of cancer after solid organ transplantation. Cancer. 2013; 119: 2300–2308. https://doi.org/10.1002/cncr.28043Brennan DC et al. Development of malignancy following solid organ transplantation. UpToDate. 2016; 10: 1–20.Hellström V.C. et al. Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation – experiences from a prospective, clinical, observational study. Acta Oncol. (Madr). 2016; 55: 774–781. https://doi.org/10.3109/0284186X.2015.1130855Noone AM et al. Cancer-attributable mortality among solid organ transplant recipients in the United States: 1987 through 2014. Cancer. 2019; 125: 2647–2655. doi: 10.1002/cncr.32136.Guillemin A. et al. Cancers solides après transplantation d’organe : épidémiologie, pronostic et spécificités de prise en charge. Bull. Cancer. Société Française du Cancer. 2017; 104: 245–257. https://doi.org/10.1016/j.bulcan.2016.12.008Endén K et al. Cancer morbidity and mortality after pediatric solid organ transplantation – a nationwide register study. Pediatr Nephrol. Pediatric Nephrology. 2020; 35: 1719–1728. https://doi.org/10.1007/s00467-020-04546-y.Shtraichman O., Ahya V.N. Malignancy after lung transplantation. Ann. Transl. Med. 2020; 8: 416–416. DOI: 10.21037/atm.2020.02.126Fogel AL, Miyar M, Teng JMC. Cutaneous Malignancies in Pediatric Solid Organ Transplant Recipients. Pediatr Dermatol. 2016; 33: 585–593. doi: 10.1111/pde.12941.Ridker P.M. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017; 390: 1833–1842. https://doi.org/10.1016/S0140-6736(17)32247-XRademacher S et al. The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients. Liver Transplant. 2017; 23: 1404–1414. doi: 10.1002/lt.24795.Wareham N.E. et al. Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation. J. Cancer Res. Clin. Oncol. Springer Berlin Heidelberg. 2019; 145: 3125–3135. https://doi.org/10.1007/s00432-019-03039-2Engels EA. Cancer in Solid Organ Transplant Recipients: There Is Still Much to Learn and Do. Am J Transplant. 2017; 17: 1967–1969. https://doi.org/10.1111/ajt.14140.Acuna S.A. et al. Cancer recurrence after solid organ transplantation: A systematic review and meta-analysis. Transplant. Rev. Elsevier Inc. 2017; 31: 240–248. https://doi.org/10.1016/j.trre.2017.08.003Legendre C et al. Long-term challenges after solid organ transplantation: Summary of expert presentations from the Sandoz 5th standalone transplantation meeting, 2017. Transplantation. 2018; 102: 1–14. doi: 10.1097/TP.0000000000002316.Legendre C et al. Long-term challenges after solid organ transplantation: Summary of expert presentations from the Sandoz 5th standalone transplantation meeting, 2017. Transplantation. 2018; 102: 1–14. doi: 10.1097/TP.0000000000002316.Wang X, Dong M. Malignancy After Lung Transplantation: How to Manage Immunosuppression? Transplant Proc. Elsevier Inc. 2020; 52: 315–320. https://doi.org/10.1016/j.transproceed.2019.09.012.Wang X, Dong M. Malignancy After Lung Transplantation: How to Manage Immunosuppression? Transplant Proc. Elsevier Inc. 2020; 52: 315–320. https://doi.org/10.1016/j.transproceed.2019.09.012.Hellström VC et al. Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation – experiences from a prospective, clinical, observational study. Acta Oncol (Madr). 2016; 55: 774–781. https://doi.org/10.3109/0284186X.2015.1130855.Hellström VC et al. Malignancies in transplanted patients: Multidisciplinary evaluation and switch to mTOR inhibitors after kidney transplantation – experiences from a prospective, clinical, observational study. Acta Oncol (Madr). 2016; 55: 774–781. https://doi.org/10.3109/0284186X.2015.1130855.Liao JB, Fisher CE, Madeleine MM. Gynecologic cancers and solid organ transplantation. Am J Transplant. 2019; 19: 1266–1277. doi: 10.1111/ajt.15292.Liao JB, Fisher CE, Madeleine MM. Gynecologic cancers and solid organ transplantation. Am J Transplant. 2019; 19: 1266–1277. doi: 10.1111/ajt.15292.Acuna SA et al. Cancer recurrence after solid organ transplantation: A systematic review and meta-analysis. Transplant Rev. Elsevier Inc. 2017; 31: 240–248. https://doi.org/10.1016/j.trre.2017.08.003.Acuna SA et al. Cancer recurrence after solid organ transplantation: A systematic review and meta-analysis. Transplant Rev. Elsevier Inc. 2017; 31: 240–248. https://doi.org/10.1016/j.trre.2017.08.003.http://www.transplant-observatory.org [Internet]. Global Observatory on Donation and Transplantation. Available from: http://www.transplant-observatory.org.http://www.transplant-observatory.org [Internet]. Global Observatory on Donation and Transplantation. Available from: http://www.transplant-observatory.org.https://gco.iarc.fr [Internet]. International Agency for Research on Cancer. Available from: https://gco.iarc.fr.https://gco.iarc.fr [Internet]. International Agency for Research on Cancer. Available from: https://gco.iarc.fr.

The authors declare that there are no conflicts of interest present.